π€ Pharmidex at the Biotech Matchmaking Event! π€
April 28, 2025
We’re excited that
Ash Alavijeh, our Head of Operations, will attend the Biotech Matchmaking Event on 29 April 2025 at the Old Divinity School, St John’s College, Cambridge.
π (Biotech Matchmaking Event - The Milner Therapeutics Institute)
Ash looks forward to meeting attendees, discussing new collaborations, and driving forward the development of innovative drug candidates.
ο»Ώ
If you're attending, let’s connect and explore new opportunities together!
We’re delighted to announce that Pharmidex will be an official sponsor of CamMedChem’25 , the renowned meeting organized by the Royal Society of Chemistry’s Biomolecular Chemistry Special Interest Group This year’s theme promises cutting-edge discussions in medicinal chemistry, biomolecular interactions and the latest trends in small molecule and chemical biology research. We’re honoured to support such a pivotal forum for scientists, drug discovery experts and academic innovators to exchange ideas, foster collaborations, and advance therapeutic discovery. π We look forward to: Learning from the powerful scientific insights shared at the meeting Exploring new partnerships that further the translation of biomolecular science into impactful therapies We can’t wait to see you in Cambridge for CamMedChem’25!
At Pharmidex , we deliver comprehensive histology solutions designed to support preclinical and clinical research with accuracy and reliability. π¬ From sample to slide, our services include: tissue processing, embedding, microtomy, routine and special staining, digital imaging and slide scanning all underpinned by rigorous quality control and expert scientific oversight. With specialist capabilities and high-throughput workflows, we help researchers generate high-quality, reproducible data across toxicology, oncology, CNS and beyond. π Learn more: pharmidex.com/histology
At Pharmidex , we are proud to offer a comprehensive preclinical platform for autoimmune disease research. Using in vivo EAE models, we combine: βοΈ Bioanalysis & biomarker profiling to quantify key cytokines and mediators of disease progression βοΈ Histological assessment, enabling detailed evaluation of inflammation, demyelination and tissue pathology across multiple organs βοΈ Pharmacological intervention studies, including established treatments such as Fingolimod for validation This integrated approach delivers a complete and translationally relevant dataset, supporting drug discovery and development programmes from mechanistic insight through to therapeutic evaluation. By combining in vivo efficacy, biomarker analysis and histology, our team provides partners with a more comprehensive understanding of disease mechanisms and treatment effects. π Learn more about our services in Histology, Biomarker Analysis, and Autoimmune Disease Models.
